Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04565418
Other study ID # NL73834.068.20
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 26, 2021
Est. completion date April 24, 2023

Study information

Verified date May 2023
Source Maastricht University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will investigate the effect of exercise training on 24h rhythms in substrate metabolism in overweight subjects with impaired glucose tolerance. Subjects will perform exercise training for 12 weeks. Before and after the exercise period, they will be admitted to research facilities for 45 hours to assess 24h rhythms in substrate metabolism. In a single-arm longitudinal design, subjects will serve as their own control.


Description:

Recent evidence shows that pre-diabetes is characterized by marked alterations in 24h substrate metabolism, indicating metabolic inflexibility with an inability to fully switch to fat oxidation during the night. Whereas exercise has been shown to promote mitochondrial function and insulin sensitivity, it is unknown to if exercise training is able to restore 24h rhythmicity in overall substrate metabolism and muscle metabolism in human subjects with pre-diabetes. In this single-arm longitudinal design, subjects will serve as their own control. Subjects will perform high-intensity interval training for 12 weeks (3x times per week) on a cycle ergometer at the research facility. Pre and post exercise, subjects will stay in a metabolic chamber and adhere to a relatively normal life-style in order to standardize the main 24h measurement period. As the primary outcome, substrate metabolism will be measured with a ventilated hood system and by indirect calorimetry in the chambers. Muscle biopsies from the vastus lateralis and frequent blood samples will also be taken over the course of the 24h. Thereby, ex-vivo skeletal muscle mitochondrial function and muscle clock gene expression will serve as the main secondary outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date April 24, 2023
Est. primary completion date December 22, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: - Caucasian - Healthy (as determined by dependent physician) - Overweight: BMI 25 - 35 kg/m2 - Prediabetic based on one or a combination of the following criteria: - Impaired Glucose Tolerance (IGT): plasma glucose values = 7.8 mmol/l and = 11.1 mmol/l 120 minutes after glucose drink consumption during OGTT in screening. - Impaired Fasting Glucose (IFG): Fasting plasma glucose = 6.1 mmol/l and = 6.9 mmol/l. - Insulin Resistance: glucose clearance rate = 360ml/kg/min, as determined using the OGIS120 model. - HbA1c of 5.7-6.4%. - Regular sleeping time (normally 7 - 9h daily) - Stable dietary habits: no weight gain or loss > 3kg in the last three months. Exclusion Criteria: - Use of anticoagulants - Previously diagnosed with type 2 diabetes - Current alcohol consumption > 20 grams alcohol/day - Extreme early bird or extreme night person (score = 30 or = 70 on MEQ-SA questionnaire) - Heavily varying sleep-wake rhythm - Nightshift work during last 3 months - Travel across > 1 time zone in the last 3 months - Significant food allergies/intolerance (seriously hampering study meals) - Using > 400mg caffeine daily (more than 4 coffee or energy drink) - Smoking

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
High-intensity interval training
3 times per week high-intensity interval training (HIIT) will be performed on a cycle ergometer for 12 weeks adding up to 36 HIIT sessions

Locations

Country Name City State
Netherlands Maastricht University Maastricht

Sponsors (1)

Lead Sponsor Collaborator
Maastricht University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in 24 rhythm in whole-body energy metabolism (energy expenditure) Energy expenditure (kJ/min) measured by indirect calorimetry measured at 8:00, 13:00, 18:00, 23:00, 04:00 of the main test day before and after 12 weeks of exerise
Primary Change in 24 rhythm in whole-body energy metabolism (glucose oxidation) Energy expenditure (kJ/min) measured by indirect calorimetry measured at 8:00, 13:00, 18:00, 23:00, 04:00 of the main test day before and after 12 weeks of exercise
Primary Change in 24 rhythm in whole-body energy metabolism (fat oxidation) Energy expenditure (kJ/min) measured by indirect calorimetry measured at 8:00, 13:00, 18:00, 23:00, 04:00 of the main test day before and after 12 weeks of exercise
Secondary Change in 24 rhythm in skeletal muscle mitochondrial respiration O2-flux (pmol/mg/s) measured with high resolution respirometry measured at 8:00, 13:00, 23:00 of the main test day before and after 12 weeks of exercise
Secondary Change in 24h rhythm in muscle protein levels of markers involved in molecular clock and mitochondrial metabolism Quantify protein levels by Western blots measured at 8:00, 13:00, 23:00 of the main test day before and after 12 weeks of exercise
Secondary Change in 24h rhythm in muscle DNA of markers involved in molecular clock and mitochondrial metabolism Quantify DNA by qPCR measured at 8:00, 13:00, 23:00 of the main test day before and after 12 weeks of exercise
Secondary Change in 24h rhythm in muscle DNA involved in molecular clock and mitochondrial metabolism. Quantify DNA by micro-array measured at 8:00, 13:00, 23:00 of the main test day before and after 12 weeks of exercise
Secondary Change in 24h rhythm in muscle mRNA markers involved in molecular clock and mitochondrial metabolism Quantify mRNA levels by micro array measured at 8:00, 13:00, 23:00 of the main test day before and after 12 weeks of exercise
Secondary Change in 24 rhythm of markers of normal 24h rhythm (cortisol) Blood cortisol levels every two hours for 24 hours beginning at 08:00 of the main test day before and after 12 weeks of exercise
Secondary Change in 24 rhythm of markers of normal 24h rhythm (melatonin) Blood melatonin levels every two hours for 24 hours beginning at 08:00 of the main test day before and after 12 weeks of exercise
Secondary Change in 24 rhythm of markers of normal 24h rhythm (core body temperature) Core body temperature measured by an ingested telemetric pill measured continuously for 24 hours on the main test day before and after 12 weeks of exercise
Secondary Change in 24h rhythm in serum glucose Serum glucose levels determined from venous blood draws every two hours for 24 hours beginning at 08:00 of the main test day before and after 12 weeks of exercise
Secondary Change in 24h rhythm in serum insulin Serum insulin levels determined from venous blood draws every two hours for 24 hours beginning at 08:00 of the main test day before and after 12 weeks of exercise
Secondary Change in 24h rhythm in serum free fatty acids (FFA) Serum FFA levels determined from venous blood draws every two hours for 24 hours beginning at 08:00 of the main test day before and after 12 weeks of exercise
Secondary Change in 24h rhythm in serum triglycerides Serum triglycerides levels determined from venous blood draws every two hours for 24 hours beginning at 08:00 of the main test day before and after 12 weeks of exercise
Secondary Change in 24h rhythm in serum cholesterol Serum cholesterol levels determined from venous blood draws every two hours for 24 hours beginning at 08:00 of the main test day before and after 12 weeks of exercise
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2